news
NHS to launch subscription service to encourage R&D
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
List view / Grid view
National Institute for Health and Care Excellence (NICE)
news
NICE endorses dacomitinib for treatment of lung cancer
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
news
Decision by NICE for the use of osimertinib to be appealed
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
news
NICE and Canadian Agency collaborate to offer parallel scientific advice
NICE in the UK and its counterpart - the Canadian Agency for Drugs and Technology in Health have collaborated to offer parallel scientific advice...
news
UK-US post-Brexit trade deal risks increased drug prices
A trade deal between the UK and USA could risk increasing drug prices in the UK, which could diminish the affordability and accessibility of the NHS...
news
NICE approves Lenvima for differentiated thyroid cancer
NICE has issued its final appraisal decision recommending reimbursement of Lenvima for the treatment of progressive, locally advanced or metastatic, differentiated thyroid carcinoma...
news
Project Hercules to lead way in Duchenne muscular dystrophy
Pharmaceutical companies are sponsoring a project to generate, align and share disease-level data across an entire condition for health technology assessments...
news
NICE recommends routine access to beta interferon drug for MS
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
news
NICE approves three quarters of drugs from the Cancer Drugs Fund
NICE has recommended sorafenib to be routinely available for patients on the NHS making it one of the 24 drugs appraised from the CDF...
news
Nexavar receives final appraisal for primary liver cancer
NICE has released a Final Appraisal Document recommending Nexavar for the treatment of patients with advanced hepatocellular carcinoma...
news
Bayer receives EU approval for Regorafenib
Bayer have announced the European Commission has granted marketing authorisation for Stivarga...
news
NICE publishes new Parkinson’s clinical guidance
Parkinson’s disease is one of the most common neurological conditions, affecting an estimated 130,000 people in the UK, with an annual incidence of around 15-20 per 100,000. It mainly affects people aged 50 or over.
news
NICE approves 3 drugs for treating plaque psoriasis in children
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
news
New improved BNF and BNFC app launched
The British National Formulary (BNF) and British National Formulary for Children (BNFC) have launched a new, faster, easier to use app...
news
NICE recommends cabozantinib for advanced renal cell cancer
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending cabozantinib for some kidney cancer patients
